Rutgers NJMS Logo

Rutgers Radiation Research Publications

 

Roger Howell Recent Lab Publications (PubMed listing)

  1. Bolcaen J, Gizawy MA, Terry SYA, Paulo A, Cornelissen B, Korde A, Engle J, Radchenko V, Howell RW. Marshalling the potential of Auger electron radiopharmaceutical therapy. J Nucl Med. 2023 Sep;64(9):1344-1351. doi: 10.2967/jnumed.122.265039. Epub 2023 Aug 17. PMID: 37591544; PMCID: PMC10478825.

  2. Katugampola S, Hobbs RF, Howell RW. Generalized methods for predicting biological response to mixed radiation types and calculating equieffective doses (EQDX). Med Phys. 2023 Aug 9. doi: 10.1002/mp.16650. Epub ahead of print. PMID: 37558637.  Editor’s Choice.

  3. Chung SK, Vargas DB, Chandler CS, Katugampola S, Veach DR, McDevitt MR, Seo SH, Vaughn BA, Rinne SS, Punzalan B, Patel M, Xu H, Guo HF, Zanzonico PB, Monette S, Yang G, Ouerfelli O, Nash GM, Cercek A, Fung EK, Howell RW, Larson SM, Cheal SM, Cheung NV. Efficacy of HER2-targeted intraperitoneal 225Ac α-pretargeted radioimmunotherapy for small-volume ovarian peritoneal carcinomatosis. J Nucl Med. 2023 Sep;64(9):1439-1445. doi: 10.2967/jnumed.122.265095. Epub 2023 Jun 22. PMID: 37348919; PMCID: PMC10478816.

  4. Katugampola S, Wang J, Howell RW. MIRD Pamphlet No. 31: MIRDcell V4, Artificial intelligence tools to formulate optimized radiopharmaceutical cocktails for therapy. J. Nucl. Med. Dec 2024, 65 (12) 1965-1973; DOI: 10.2967/jnumed.123.267238. Received 2024 Alavi-Mandell Award from SNMMI.

  5. Hargrove D, Ranjbar S, Darji M, Nam S, Dawson RJ, Katugampola S, Lin X, Brown A, Carrasco-Rojas N, Goodwin C, Howell RW, Bolch WE, Jay M, Salner A, Lu X. Tumor specific delivery and radiation-enhanced tumor penetration of mesoporous silica nanoparticles for effective radionuclide therapy of ovarian peritoneal metastasis. Int J Pharm. 2025 Jan 25;669:125071. doi: 10.1016/j.ijpharm.2024.125071. Epub 2024 Dec 9. PMID: 39662854.

  6. Macsuka MJ, Howell RW, Vallis KA, McGowan DR. A novel fast strategy to calculate equieffective doses under different dose rate conditions. Med Phys. 2025 Feb 15. doi: 10.1002/mp.17688. Epub ahead of print. PMID: 39955266.

  7. Buchsbaum JC, VanBrocklin HF, Hernandez R, O'Brien EM, Hennkens HM, Medvedev DG, Howell RW, Escorcia FE, Dewaraja YK, Jha AK, Kapadia AJ, Agasthya G, Rahmim A, Saboury B, Myhre K, Davern S. Computational Modeling to Advance Novel Medical Isotopes for Radiotheranostics: A DOE-NIH Joint Workshop Executive Summary. Radiat Res. 2025 Jul 1;204(1):75-79. doi: 10.1667/RADE-25-00MR1.1. PMID: 40314593.

  8. Gadiyar V, Pulica R, Aquib A, Tranos JA, Varsanyi C, Frederick T, Wang Z, Almansa LF, Gaspers L, De Lorenzo MS, Kotenko SV, Tripathi S, Howell RW, Choudhary A, Calianese DC, Birge RB. Phospholipid Scramblases TMEM16F and Xkr8 mediate distinct features of Phosphatidylserine (PS) externalization and immune suppression to promote tumor growth. Cell Death Discov. 2025 Nov 6;11(1):506. doi: 10.1038/s41420-025-02789-y. PMID: 41198619; PMCID: PMC12592367.

  9. Tallam H, Nair R, Sarkar A, Katugampola S, Sofou S, Howell RW. Preirradiation of Spheroids with 225Ac-Trastuzumab Improves Penetration of 225Ac-Liposomes and MIRDcell Predictions of Responses to Drug Cocktails. J Nucl Med. 2025 Aug 1;66(8):1278-1283. doi: 10.2967/jnumed.124.269273. PMID: 40506236. Received 2026 Alavi-Mandell Award from SNMMI.

  10. Rinne SS, Vargas DB, Vaughn BA, Katugampola S, Miller BW, Veach DR, Punzalan B, de Stanchina E, Yaeger R, Miranda IC, Xu H, Guo H, Schwartz J, Fung EK, Howell RW, Larson SM, Cheung NV, Cheal SM. Comparison of targeting two antigens (GPA33 versus HER2) for 225Ac-pretargeted alpha-radioimmunotherapy of colorectal cancer. Theranostics. 2025 Jun 20;15(15):7489-7500. doi: 10.7150/thno.116062. PMID: 40756357; PMCID: PMC12315807.

Edouard Azzam Lab Recent Publications (PubMed listing)